A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells

Japanese Journal of Cancer Research

Volumn 90, Issue 6, 1999, Pages 691-698

  Ohyama, Tomoko ^a   Li, Yin ^a   Utsugi, Teruhiro ^b   Irie, Shinji ^c   Yamada, Yuji ^b   Sato, Taka Aki ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c RIKEN TSUKUBA INSTITUTE   (Japan)

Author keywords

Apoptosis; Bcl 2; Protease; TAS 103; Topoisomerase inhibitor

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; CYSTEINE PROTEINASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

EID: 0032774554     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00802.x     Document Type: Article

References (38)

1. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462 (1995).
2. Steller, H. Mechanisms and genes of cellular suicide. Science, 267, 1445-1449 (1995).
3. Jacobson, M. D., Weil, M. and Raff, M. C. Programmed cell death in animal development. Cell, 88, 347-354 (1997).
4. Kerr, J. F., Wyllie, A. H. and Currie, A. R. Apoptosis. A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br.J.Cancer, 26, 239-257 (1972).
5. Hengartner, M. O. and Horvitz, H. R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell, 76, 665-676 (1994).
6. Korsmeyer, S. J. Regulators of cell death. Trends Genet., 11, 101-105 (1995).
7. Hockenbery, F. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L. and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75, 241-251 (1993).
8. Kane, D. J., Sarafian, T. A., Anton, R., Hahn, H., Gralla, E. B., Valentine, F. S., Ordm, T. and Bredesen, D. E. Bcl-2 inhibition of neural death: decreased generation of reactive oxgen species. Science, 262, 1274-1277 (1993).
9. Reed, J. C. Bcl-2 and regulation of programed cell death. J. Cell Biol., 124, 1-6 (1994).
10. Cohen, G. M. Caspases: the executioners of apoptosis. Biochem. J., 326, 1-16 (1997).
11. Salvesen, G. S. and Dixit, V. M. Caspases: intracellular signaling by proteolysis. Cell, 91, 443-446 (1997).
12. Whyte, M. ICE/CED-3 proteases in apoptosis. Trends Cell Biol., 6, 245-248 (1996).
13. Cryns, V. and Yuan, J. Proteases to die for (review). Genes Dev., 12, 1551-1570 (1998).
14. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A. and Yuan, J. Induction of apoptosis in fibroblasts by IL-1b-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75, 653-660 (1993).
15. Berger, J. M. Structure of DNA topoisomerases (review). Biochim. Biophys. Acta, 1400, 3-18 (1998).
16. Osheroff, N. DNA topoisomerases (review). Biochim. Biophys. Acta, 1400, 1-2 (1998).
17. Benjamin, C. W., Hiebsch, R. R. and Jones, D. A. Caspase activation in MCF7 cells responding to etoposide treatment. Mol. Pharmacol., 53, 446-450 (1998).
18. Dubrez, L., Savoy, I., Hamman, A. and Solary, E. Pivotal role of a DEVD-sensitive step in etoposide-induced and FAS-mediated apoptotic pathways. EMBO J., 15, 5504-5512 (1996).
19. Shao, R. G., Cao, C. X. and Pommier, Y. Activation of PKCα downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells. J. Biol. Chem., 272, 31321 -31325 (1997).
20. Garcia-Bermejo, L., Perez, C., Vilaboa, N. E., Blas, E. and Aller, P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promyelocytic leukemia cells. J. Cell Sci., 111, 637-644 (1998).
21. Hande, K. R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta, 1400, 173-184 (1998).
22. Utsugi, T., Aoyagi, K., Asao, T., Okazaki, S., Aoyagi, Y., Sano, M., Wierzba, K. and Yamada, Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn. J. Cancer Res., 88, 992-1002 (1997).
23. Martins, L. M., Mesner, P. W., Basi, K. G, Sinha, S., Tung, J. S., Svingen, P. A., Madden, B. J., Takahashi, A., McCormick, D. J., Earnshaw, W. C. and Kaufmann, S. H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90, 4283-4296 (1997).
24. Adjei, P. N., Kaufmann, S. H., Leung, W. Y., Mao, F. and Gores, G. J. Selective induction of apoptosis in Hep 3B cells by topoisomerase inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease CPP32. J. Clin. Invest., 98, 2588-2596 (1997).
25. Sarin, A., Williams, M. S., Alexander-Miller, M. A., Berzofsky, J. A., Zacharchuk, C. M. and Henkart, P. A. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity, 6, 209-215 (1997).
26. Hansen, M. B., Nielsen, S. E. and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth and cell kill. Immunol. Methods, 119, 203-210 (1989).
27. Stefanis, L., Park, D. S., Yan, C. Y. I., Farinelli, S. E., Troy, C. M., Shelanski, M. L. and Green, L. A. Induction of CPP32-like activity in PC12 cells by withdrawal of tropic support. J. Biol. Chem., 271, 30663-30671 (1996).
28. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. and Taguchi, T. A phage II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10, 16-20 (1992).
29. Armand, J. P., Ducreux, M., Mahjoubi, M., Abigerges, D., Bugat, R., Chabot, G., Herait, P., de Forni, M. and Rougier, P. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer, 31A, 1283-1287 (1995).
30. O'Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S. and Wittes, R. E. Etoposide (VP-16-213). Current status of an active anticancer drug. N. Engl. J. Med., 312, 692-700 (1985).
31. Barnes, S., Peterson, T. G. and Coward, L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J. Cell. Biochem. Suppl., 22, 181-187 (1995).
32. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048 (1989).
33. Holden, J. A., Rolfson, D. H. and Wittwer, C. T. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry, 29, 2127-2134 (1990).
34. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F. and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50, 7962-7965 (1990).
35. Pommier, Y. and Shimizu, T. Camptothecin-induced apoptosis in p53-null leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia, 11, 1238-1244 (1997).
36. Kluck, R. M., Martin, S. J., Hoffman, B. M., Zhou, J. S., Green, D. R. and Newmeyer, D. D. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J., 16, 4639-4649 (1997).
37. Kluck, R. M., Bossy-Wetzel, E., Green, D. R. and Newmeyer, D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science, 275, 1132-1136 (1997).
38. Yang, E. and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood, 88, 386-401 (1996).